+44 (0)1223 839557
info@rxcelerate.com
  • ABOUT
    • VISION & MISSION
    • OUR STORY
    • LEADERSHIP
    • CAREERS
      • HOW WE HIRE
      • CURRENT VACANCIES
  • CAPABILITIES
    • BIOLOGY
      • IN VITRO
      • IN VIVO
      • SYSTEMS BIOLOGY
      • TRANSLATIONAL BIOMARKERS
      • MICROSCOPY
    • CHEMISTRY
      • In Silico Molecular Modelling
      • Medicinal Chemistry
      • Process & Scale Up
      • BIOANALYTICAL
    • PROGRAMME DESIGN & MANAGEMENT
    • GxP
  • THERAPEUTIC AREAS
  • MEDIA
  • RxCAPITAL
  • LICENCES & AFFILIATIONS
  • CONTACT
  • Privacy Policy

RxCelerate acquires Methuselah Health and launches ProQuant™ world-beating proteomics service

How I made it – From miner’s daughter to leading biotech boss

RxCelerate launch RxNfinity™: a next-generation machine learning-enabled small molecule discovery platform

SPR SEPARATOR

RxCelerate launch Galaxy™: a next-generation antibody discovery platform

SPR SEPARATOR

Leading UK drug developer RxCelerate opens first US base in Boston

SPR SEPARATOR

RxCelerate acquires Total Scientific Ltd

SPR SEPARATOR

RxCelerate acquires The Cambridge Partnership Ltd

SPR SEPARATOR

RxCelerate Opens UK-Based Chemistry Operations

SPR SEPARATOR

RxCelerate acquires Prosarix

SPR SEPARATOR

RxCelerate Expands

1 2 Next

ALL CONTENT © RxCELERATE LTD